- BreathID Hp
- Events & Webinars
- Patient Information
Exalenz Bioscience to Present at Upcoming Investor Conferences
Modi’in, Israel – September 29, 2014 --Exalenz Bioscience (TASE: EXEN), a leader in developing and marketing non-invasive medical devices for diagnosing and monitoring a range of gastrointestinal and liver diseases, announced today Lawrence Cohen, CEO will participate in upcoming investor conferences.
The BTIG Emerging Technologies in Healthcare Diagnostics Conference taking place at the Benjamin Hotel in New York September 29 and 30th. Mr. Cohen will participate in the following panel discussions:
“Diagnostics for Abdominal Pain”, taking place on Monday, September 29th at 3:00 PM ET.
“Establishing Reimbursement for Novel Tests”, taking place on Tuesday, September 30th at 2:20 PM ET.
The JMP Securities Life Sciences Private Company Conference taking place at the Parker Meridian Hotel in New York on Friday, October 17.
About Exalenz Bioscience
Exalenz Bioscience develops diagnostic and monitoring systems that use the breath to diagnose and help manage GI and liver conditions. The company’s flagship BreathID Hp product detects the presence of the H. pylori bacteria the cause of various illnesses including gastric cancer. Exalenz holds regulatory approvals in Europe the US and Israel for H. pylori detection and is currently in the process of obtaining approvals for additional applications.
Forward-looking information: estimates made by the company included in this publication are considered forward-looking information and there is no assurance that said information will be realized. Company estimates are based on various business assumptions experience and professional information. These estimates may not be realized in whole or in part or may be realized in a manner significantly different from that anticipated by the company for various reasons including reasons not within the control of the company
Lazar Partners Ltd.
T: (212) 867-1768